摘要
目的:研究中药丹参的有效成分丹酚酸B盐抗肝纤维化作用的机制。方法:Wistar大鼠24只随机分为正常对照组、模型组和丹酚酸B盐治疗组。采用二甲基亚硝胺诱导大鼠肝纤维化模型,丹酚酸B盐治疗组在造模4周后给予丹酚酸B盐治疗4周。治疗结束后,用盐酸水解法检测全部大鼠肝组织中羟脯氨酸的含量,用Western印迹法检测肝组织Ⅰ型胶原蛋白、转化生长因子β1(transforminggrowthfactor-beta1,TGF-β1)、转化生长因子β受体Ⅰ(transforminggrowthfactor-betareceptortypeⅠ,TβRⅠ)、转化生长因子β受体Ⅱ(transforminggrowthfactor-betareceptortypeⅡ,TβRⅡ)蛋白的表达。结果:模型组大鼠肝组织中羟脯氨酸的含量、Ⅰ型胶原蛋白、TGF-β1及其受体TβRⅠ和TβRⅡ蛋白的表达较正常对照组均有显著增加,而丹酚酸B盐治疗组的上述指标与模型组比较则均有不同程度的下降。结论:丹酚酸B盐具有明显的抗肝纤维化作用,其作用机制与抑制TGF-β1及其受体蛋白的表达有关。
Objective： To study the therapeutic mechanism of salvianolic acid B （SA-B） in treating hepatic fibrosis. Methods： Twenty-four Wistar rats were randomly divided into 3 groups： normal control group,untreated group and SA-B-treated group. Rats in the untreated and SA-B-treated groups were injected intraperitoneally with 0, 5% dimethylnitrosamine （DMN） for 4 weeks, daily for 3 days each week at a dose of 10 μg/kg, to induce hepatic fibrosis, Then, rats in the SA-B-treated group were given SA-B orally for another 4 weeks. Hydroxyproline （Hyp） contents in liver tissue of the rats in 3 groups were determined with HCI hydrolysis, and collagen type Ⅰ , transforming growth factor-beta 1 （TGF-β1）, transforming growth factorbeta receptor type Ⅰ （TβR Ⅰ ） and transforming growth factor-beta receptor type Ⅱ （TβF Ⅱ ） were detected by Western blotting. Results： The Hyp content and the expressions of collagen type I , TGF-β1, TβR Ⅰ and TβR Ⅱ in the liver tissue of rats in the untreated group increased significantly as compared with those in the normal control group, while those in SA-B-treated group decreased significantly as compared with those in the untreatedgroup. Conclusion： The therapeutic mechanism of SA-B in treating hepatic fibrosis may be related to inhibiting the expressions of TGF-β1 and its receptors.
出处
《中西医结合学报》
CAS
2005年第4期286-289,共4页
Journal of Chinese Integrative Medicine
基金
国家自然科学基金资助项目(No.39970899)
